UroGen Pharma URGN Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's accounts receivable?
- UroGen Pharma (URGN) reported accounts receivable of $55.41M in Q1 2026.
- How has UroGen Pharma's accounts receivable changed year-over-year?
- UroGen Pharma's accounts receivable increased by 182.2% year-over-year, from $19.64M to $55.41M.
- What is the long-term trend for UroGen Pharma's accounts receivable?
- Over 5 years (2020 to 2025), UroGen Pharma's accounts receivable has grown at a 36.2% compound annual growth rate (CAGR), from $7.05M to $33.08M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.